Back to Authors

Arya, Nandini

https://orcid.org/0009-0002-2289-4423

Mayo Clinic

University of Michigan

Citations 3

Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer
Henstridge, Aylin Z. , Azorsa, Peter, Arya, Nandini , Elhossiny, Ahmed M. , Kadiyala, Padma , Goldwasser, Molly , Branch, Georgina , Sahai, Vaibhav , Peterson, Nicole , Machicado, Jorge D. , Kwon, Richard S. , Schulman, Allison R. , Wamsteker, Erik‐Jan , Philips, George, Menees, Stacy B. , Xia, Jonathan Y. , Hogenson, Tara L. , Rao, Arvind , Shi, Jiaqi , Frankel, Timothy L. , Bednar, Filip , Magliano, Marina Pasca di , Lyssiotis, Costas A. , Truty, Mark J. , Fernández-Zapico, Martín E. , Carpenter, Eileen S. , Azorsa, Peter A , Philips, George M , Pasca di Magliano, Marina , Lyssiotis, Costas A , Sahai, Vaibhav

Cancer Research | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/0008-5472.can-26-0823 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). Cytotoxic combination chemotherapy treatments are the mainstay of PDAC therapy, but patients rapidly develop chemoresistance, highlighting the need to elucidate how chemotherapy alters the TME and whether these changes drive chemoresistance. Here, we examined matched pre- and post-treatment tissue specimens using single-cell RNA-sequencing and found near-universal enrichment after treatment of axonal guidance genes in cancer-associated fibroblasts (CAFs). These neural CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrent lesions had the highest prevalence of neural CAFs versus primary tumors and untreated metastases. Neural CAFs showed elevated non-canonical WNT mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Additionally, in vitro studies revealed enrichment of axonal guidance genes in patient-derived CAF lines upon exposure to chemotherapy or tumor cells. Altogether, these findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising therapeutic target for this disease.
Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer
Henstridge, Aylin Z. , Arya, Nandini , Kadiyala, Padma , Branch, Georgina , Peterson, Nicole , Kwon, Richard S. , Schulman, Allison R. , Wamsteker, Erik, Philips, George, Menees, Stacy B. , Hogenson, Tara L., Rao, Arvind, Shi, Jiaqi , Bednar, Filip , Lyssiotis, Costas A. , Truty, Mark J. , Fernández-Zapico, Martín E. , Shi, Jiaqi , Bednar, Filip , Pasca di Magliano, Marina , Lyssiotis, Costas A , Carpenter, Eileen S , Elhossiny, Ahmed M. , Sahai, Vaibhav , Machicado, Jorge D. , Xia, Jonathan Y. , Hogenson, Tara L., Rao, Arvind, Frankel, Timothy L. , Magliano, Marina Pasca di , Carpenter, Eileen S.

No container title available | December 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.01.691614 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). How chemotherapy alters the TME, and whether these changes drive chemoresistance, is poorly understood. We examined matched pre- and post-treatment tissue specimens and found near-universal enrichment of axonal guidance genes in cancer-associated fibroblasts (CAFs) after treatment. These CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrence lesions had the highest prevalence of these CAFs versus primary tumors and untreated metastasis. These CAFs showed elevated non-canonical Wnt mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Our findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising target for this disease. Statement of Significance Therapeutic resistance remains a major challenge in pancreatic cancer. Our findings shed light on the changes in the complex tumor microenvironment in response to chemotherapy and identify fibroblasts high in axonal-guidance genes that may drive tumor progression and chemoresistance, thus uncovering a potential avenue for targeting pancreatic cancer.
Abstract B079: An increase in neural cancer associated fibroblasts following exposure to chemotherapy in pancreatic ductal adenocarcinoma
Henstridge, Aylin Z. , Kadiyala, Padma , Elhoissiny, Ahmed, Liu, Jianhua , Branch, Georgina , Arya, Nandini , Sahai, Vaibhav , Peterson, Nicole , Machicado, Jorge D. , Kwon, Richard S. , Schulman, Allison R. , Wamsteker, Erik, Phillips, George, Fernández-Zapico, Martín E. , Truty, Mark J. , Bednar, Fillip, Lyssiotis, Costas A. , Lyssiotis, Costas A , Sahai, Vaibhav , Frankel, Timothy L. , Bednar, Filip , Magliano, Marina Pasca di , Carpenter, Eileen S.

Cancer Research | September 28, 2025 | Volume: 85 | Issue: 18_Supplement_3 | Pages: B079-B079

10.1158/1538-7445.pancreatic25-b079 Get It

Abstract Pancreatic adenocarcinoma (PDA) has poor response to chemotherapy with a strong likelihood of cancer recurrence. While previous studies have examined patient samples collected before and after chemotherapy, few have analyzed matched samples from the same patients that allow us to deconvolute interpatient heterogeneity, a large limitation to PDA studies. Here, we study the effects of chemotherapy on tumor cells and their surrounding microenvironment using scRNA sequencing of matched pre- and post- treatment tissue biopsies from 5 patients. We utilized the Seurat v4 pipeline to observe transcriptomic differences and corresponding putative cellular interactions in both treatment states. Unsurprisingly, we found insufficient tumor epithelial cells post-treatment due to the intended cytotoxic effects of chemotherapy, leading us to focus on the tumor microenvironment where we had sufficient cells to analyze. We identified that immune cells in the TME are heterogeneously affected by chemotherapy treatment with patient specific differences, but we did identify a unanimous increase in CXCR4 in CD4 and CD8 positive T cells after treatment. Analysis of CAFs revealed that a subset of fibroblasts lose myofibroblastic features and increasingly acquire 'neural'-like features after treatment. This suggests that chemotherapy-altered fibroblasts may contribute to a pro-tumor microenvironment that facilitates recurrence through neuron–CAF–tumor interactions. Through inferred ligand-receptor pairs identified with the CellChat v2 pipeline, we observed that increased CXCL12 in these neural CAFs interacts with the increased CXCR4 on T-cells. We validated the expression of these genes in patients by staining human patient PDAC tissues (both treated and treatment naïve tissues) for neural genes that were highly enriched post-treatment in our single cell sequencing dataset. We have also begun inhibiting these genes of interest in CAFs and are exploring the effects of these ‘neural’-CAFs on patient-derived tumor organoids in culture. Citation Format: Aylin Z. Henstridge, Padma Kadiyala, Ahmed Elhoissiny, Jianhua Liu, Georgina Branch, Nandini Arya, Vaibhav Sahai, Nicole Peterson, Jorge Machicado, Richard Kwon, Allison Schulman, Erik Wamsteker, George Phillips, Martin Fernandez-Zapico, Mark Truty, Timothy Frankel, Fillip Bednar, Marina Pasca di Magliano, Costas Lyssiotis, Eileen S. Carpenter. An increase in neural cancer associated fibroblasts following exposure to chemotherapy in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr B079.